Belzutifan PK in ESRD

Phase 1, open-label trial of belzutifan in von Hippel–Lindau disease (VHL) and renal cell carcinoma (RCC) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to Infinity at 72 hours, Area Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to 24 at 24 hours and 3 more. Started Jul 2022; status: completed.